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Abstract We have designed a chimeric promoter that can be
stimulated by various pro-inflammatory mediators and so drive
the expression of therapeutic genes under inflammatory condi-
tions. The promoter has two parts, the [3247/+20] fragment of
the human type IIA secreted phospholipase A2 gene promoter,
which is stimulated by the pro-inflammatory cytokine inter-
leukin-1L (IL-1L), and a double peroxisome proliferator-
activated receptor response element that is activated by some
eicosanoids and by non-steroidal anti-inflammatory drugs
(NSAIDs). Transfection experiments using rabbit articular
chondrocytes in primary culture showed that this chimeric
promoter produced a low basal activity and was induced by
NSAIDs, WY-14643, IL-1L, and 15-deoxy v12;14 prostaglandin
J2. The latter two compounds stimulated the promoter
synergistically. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Several studies have shown that sPLA2-IIA (type IIA se-
creted phospholipase A2), also known as ‘synovial PLA2’, is
involved in in£ammatory diseases such as atherosclerosis and
rheumatoid arthritis. The gene coding for sPLA2-IIA has been
cloned from patients su¡ering from rheumatoid arthritis [1].
This enzyme releases arachidonic acid from cell membrane
phospholipids, thus providing the substrate for prostaglandin
synthesis. The gene has no detectable basal level of transcrip-
tion in a number of cell lines and tissues. However, the
amount of its mRNA increases markedly in cells exposed to
pro-in£ammatory cytokines, in particular interleukin-1L (IL-
1L) [2]. The human sPLA2 gene promoter has been extensively
studied in our laboratory [3^5]; we have shown that stimu-
lation by IL-1L triggers the binding of the transcription fac-
tors C/EBP L and N (CAAT/enhancer binding protein). This
promoter is also stimulated (two-fold) by glucocorticoids
through a half-GRE.
PPARs (peroxisome proliferator-activated receptor) are li-
gand-induced transcription factors belonging to the nuclear
receptor family. PPARs form heterodimers with the retinoic
X receptor (RXR), which then bind to a speci¢c element, the
PPRE (PPAR response element), in the promoter region of
the target gene. Three PPAR isotypes have been identi¢ed:
PPARK (mainly in liver), PPARL/N (quite ubiquitous) and
PPARQ (mainly in adipose tissue) [6], and two isoforms, K
and Q, were found in chondrocytes [7]. They were ¢rst believed
to mediate the e¡ects of synthetic compounds, peroxisome
proliferators, on transcription. But, PPARs are also activated
by several natural and synthetic molecules, including hypo-
lipidemic ¢brate drugs, anti-diabetic thiazolidinediones, acyl
CoA, some eicosanoids and fatty acids like arachidonic acid.
PPARK is especially sensitive to leukotriene B4 [8], while
PPARQ is strongly activated by 15-deoxy v12;14 prostaglandin
J2 (PGJ2) [9]. Non-steroidal anti-in£ammatory drugs
(NSAIDs), such as ibuprofen and indomethacin, bind and
activate both isoforms of PPAR [10].
We have constructed a chimeric promoter that can be
induced in an in£ammatory context and may thus be used
for the gene therapy of diseases involving in£ammation. This
promoter consists of two transcription units: the proximal
sequence is part of the sPLA2-IIA gene promoter and the
distal part contains two PPRE. This report describes the
responses of these two parts to in£ammatory stimuli, IL-
1L for the sPLA2-IIA part and certain eicosanoids for the
PPRE, in primary cultures of chondrocytes. The results
demonstrate that the short human sPLA2 gene promoter
triggers a strong response to IL-1L in the vicinity of
PPRE. Moreover, this synthetic hybrid promoter is not
only stimulated by all these compounds (IL-1L, WY-14643,
PGJ2), but also by indomethacin and ibuprofen. Lastly,
these activators can stimulate greater transcription when
they act together, probably due to cross-talking between
the transcription factors.
2. Materials and methods
2.1. Plasmid constructs
The [3247/+20] fragment of the human sPLA2-IIA promoter was
inserted into a PUC-SH-CAT plasmid. The various units ^ direct
repeat 1 (DR1), (DR1)2-18, (DR1)2-21 and (DR1)2-30 ^ were inserted
upstream into Asp718/XbaI restriction sites (Fig. 1A).
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The PPARK, PPARQ and RXR expression vectors were kindly do-
nated by Dr W. Wahli (Lausanne, Switzerland).
2.2. Chondrocyte culture and transfection
Chondrocytes were isolated from 3-week-old female ‘Fauve de
Bourgogne’ rabbits and transfected as previously described [2]. L-Ga-
lactosidase activity was measured to correct for the transfection e⁄-
ciency. [3]
2.3. Preparation of COS-1 whole cell extracts
COS-1 cells were transfected as described [11] with 20 Wg PPARK,
PPARQ or RXR expression vectors.
2.4. Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as described [3] and the retarded complexes
were quanti¢ed using a phosphorimager (Imagequant software).
The equations used to calculate the cooperativity ratio were
adapted from Tsai et al. [12] for the (DR)2-x units (x is the number
of bp separating the two DR1 centers); it corresponds to the ratio
between the Km for the formation of the double dimer and the Km for
the formation of the single dimer.
3. Results
3.1. Design of an optimal PPRE
We designed four sequences containing di¡erent arrange-
ments of PPRE (Fig. 1A) to produce a readily induced eico-
sanoid response element. The classical PPRE sequence, or
DR1, consists of a direct repeat of AGGTCA separated by
1 bp. We increased the a⁄nity of the PPARs for DR1 by
adding a CAAAACT sequence upstream of the ¢rst AGGT-
CA. (DR1)2-x consisted of two DR1, separated by 18, 21 or
30 bp, center to center. In the case of (DR1)2-18, the AGGT-
CA sequence of the ¢rst PPRE overlapped the CAAAACT 5P-
sequence of the second PPRE by 2 bp. The two PPREs of
(DR1)2-21 and (DR1)2-30 are separated by two or three
DNA turns, respectively (21 and 30 bp).
3.1.1. PPAR binding to the PPRE constructs. We then
tested the binding of PPARK and -Q isoforms to these syn-
thetic response elements. We performed EMSA with increas-
ing amounts of COS-1 whole cell extracts enriched with either
PPARK (Fig. 1B) or PPARQ (Fig. 1C), and in both cases we
added whole cell extracts enriched with RXR, as PPAR need
to heterodimerize with RXR to bind the PPRE. The PPAR/
RXR ratio was 3/1 to avoid the formation of the RXR/RXR
homodimer. PPARK formed a single complex, corresponding
to a PPAR/RXR heterodimer, with the DR1. (DR1)2-18,
(DR1)2-21 and (DR1)2-30 formed two complexes. The ¢rst
co-migrated with the dimeric complex (complex II) and cor-
responded to a PPAR/RXR dimer. Another, slowly migrating
complex, was also produced by these constructs. This high-
molecular-weight complex probably corresponded to a PPAR/
RXR double heterodimer (complex IV). The amounts and
proportions of complexes II and IV produced in the presence
of each (DR1)2-x were di¡erent. For PPARK, the coopera-
tivity ratio was the same for all the (DR1)2-x constructs
(about 10), which suggests that the PPARK/RXR double het-
erodimer bound cooperatively to these sequences, regardless
of the distance between the two DR1.
The experiments with PPARQ showed di¡erences in the
proportions of complexes II and IV depending on the PPRE
structure (Fig. 1C). Complex II contained 35^40% of the total
radioactivity of the probe in the presence of (DR1)2-18 and
(DR1)2-30 units. In contrast, complex II never contained
more than 20% of the total radioactivity in the presence of
Fig. 1. Cooperative binding of the PPAR/RXR to the PPRE se-
quences. A: Sequences of the various PPRE arrangements. DR1
half-sites are in bold type. Radiolabeled DR1, (DR1)2-18, (DR1)2-
21 or (DR1)2-30 were incubated with increasing amounts (in Wl) of
COS-1 whole cell extract enriched with PPARQ (B) or PPARK (C).
Arrowheads indicate the free probe (Probe), complex II (II) or com-
plex IV (IV) on each autoradiogram. Results are expressed as the
percentage of the total radioactivity in each band. Squares represent
complex II, diamonds represent complex IV and triangles represent
free probe. (R) is the cooperativity ratio. The curves are the means
of three di¡erent EMSA.
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the (DR1)2-21 unit, while complex IV contained 80%. The
cooperativity ratios for (DR1)2-18 and (DR1)2-30 were very
similar (about 10), whereas that of (DR1)2-21 was higher
(34 þ 11). These ¢ndings show that the three units coopera-
tively bind two PPARQ/RXR dimers and that (DR1)2-21 elic-
its greater cooperative binding.
3.1.2. Functionality of the di¡erent PPRE constructs. We
tested the capacity of the various constructs to stimulate tran-
scription. Primary cultures of chondrocytes were transiently
transfected with either [3247/+20]-CAT, (DR1)-[3247/+20]-
CAT, (DR1)2-18-[3247/+20]-CAT, (DR1)2-21-[3247/+20]-
CAT, or (DR1)2-30-[3247/+20]-CAT (Fig. 2) and stimulated
with PGJ2, a potent PPARQ activator, or WY-14643, a potent
PPARK activator. The basal activities of the ¢ve constructs
tested were very di¡erent. Those of [3247/+20] and DR1-
[3247/+20] were three- to four-fold higher than that of
(DR1)2-x constructs. Neither PGJ2 nor WY-14643 activated
the transcription of [3247/+20] or DR1-[3247/+20] con-
structs, but PGJ2 and WY-14643 both stimulated the tran-
scriptions of (DR1)2-18, -21 and -30 nearly three-fold. These
three constructs also had very low basal activities that could
prevent the ‘leakage’ of the promoter. The EMSA and trans-
fection experiments led us to select (DR1)2-21-[3247/+20] as
the most e⁄cient inducible promoter. This sequence bound
PPARK/RXR and PPARQ/RXR most cooperatively, and pro-
moted transcription most e⁄ciently under stimulation.
3.2. E¡ects of IL-1L, eicosanoids and glucocorticoids on the
promoter activity
We investigated the transcription elicited by the promoter
in response to di¡erent stimulations. The [3247/+20] sPLA2
part of the promoter contains a C/EBP site at [3200/3191]
that mediates activation by IL-1L and a half-GRE site at
[3229/3224] [3]. The PPRE should allow the promoter to
respond to PGJ2, WY-14643 or any other PPAR ligand. IL-
1L produced a moderate (two-fold) increase in transcription,
and PGJ2 stimulated transcription less than three-fold (Fig.
3). Incubation with a combination of these drugs resulted in a
10-fold increase in transcription. The PPARK activator WY-
14643 produced 3.5-fold more transcription than the basal
activity and IL-1L and WY-14643 acted additively (7.5-fold
stimulation). The synthetic glucocorticoid, dexamethasone
(Dex), activated the sPLA2-IIA promoter two-fold [5], but it
produced a four-fold increase in transcription with the syn-
thetic promoter. PGJ2 plus Dex acted additively (eight-fold
increase in transcription), whereas WY-14643 plus Dex had a
less marked action (¢ve-fold stimulation). IL-1L and Dex did
not act additively, as described by Massaad et al. on the
sPLA2-IIA promoter [3] and combinations of Dex+IL-
1L+PGJ2 or Dex+IL-1L+WY-14643 did not increase the
stimulation produced by Dex+PGJ2 or Dex+WY-14643.
We compared the transcription elicited by the synthetic
promoter to that of strong virus promoters commonly used
in gene therapy. The basal activity of the (DR1)2-21 promoter
was weaker (2 and 5% respectively) than those of SV-40 (Sim-
ian Virus 40) or RSV (Rous Sarcoma Virus). The various
ligands all signi¢cantly stimulated the synthetic eukaryote
promoter: 30% of SV-40, and 40% of RSV activities (data
not shown).
3.3. E¡ects of NSAIDs on the promoter activity
Patients su¡ering from in£ammatory diseases are usually
Fig. 2. Functionality of the PPREs. Primary cultures of chondro-
cytes were transfected with one of these constructs: pUC-SH-[3247/
+20]-CAT, pUC-SH-DR1-[3247/+20]-CAT, pUC-SH-(DR1)2-18-
[3247/+20]-CAT, pUC-SH-(DR1)2-21-[3247/+20]-CAT or pUC-SH-
(DR1)2-30-[3247/+20]-CAT and stimulated with PGJ2 (5.1036 M)
or WY-14643 (1034 M). Each point is the mean þ S.E.M. of four in-
dependent experiments performed in duplicate. Data are expressed
as stimulated transcription relative to the pUC-SH-(DR1)2-21-
[3247/+20]-CAT basal activity.
Fig. 3. A: Diagram showing the chimeric promoter, transcription
factor binding sites and related putative inducers. B: E¡ects of IL-
1L, PGJ2, WY-14643 and Dex on chimeric promoter activity. Pri-
mary cultures of chondrocytes were transfected with pUC-SH-
(DR1)2-21-[3247/20]-CAT and cultured with IL-1L (10 ng/ml),
PGJ2 (5.1036 M), WY-14643 (1034 M), Dex (1037 M) or combina-
tions of these inducers. Each point is the mean þ S.E.M. of six inde-
pendent experiments performed in duplicate. Data are expressed as
fold induction compared to unstimulated cells. The combination of
WY-14643 and PGJ2 was highly toxic to the chondrocytes,
although the vehicle did not a¡ect them.
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treated with NSAIDs. These drugs not only inhibit cycloox-
ygenase activity, they also bind to and activate PPAR-K and
-Q isoforms [10]. We therefore tested the e¡ects of indometha-
cin and ibuprofen on the transcription triggered by the syn-
thetic promoter (Fig. 4). Indomethacin activated the construct
3.5-fold and had an additive e¡ect with IL-1L (¢ve-fold acti-
vation). Ibuprofen increased transcription ¢ve-fold and acted
additively with IL-1L (seven-fold activation). The combina-
tion of either indomethacin or ibuprofen with Dex had no
additive e¡ect (data not shown).
4. Discussion
We have constructed a promoter that can be modulated by
the various pro-in£ammatory mediators present in tissues in
in£ammatory diseases like Crohn’s disease [13], arthritis [14],
atherosclerosis [15] and acute respiratory distress syndrome
[16]. We wanted it to have a low basal activity under non-
in£ammatory conditions but to be very active in the presence
of in£ammation. This promoter is a potentially useful clinical
tool. It could be used to develop new protocols of gene ther-
apy, in which the synthesis of an anti-in£ammatory or anti-
destructive protein is regulated in response to the patient’s
endogenous signals. Hence, the amount of the curative protein
produced would vary with the intensity and duration of the
in£ammatory condition. We therefore used a short promoter
that acts well in chondrocytes fused to DNA elements that
respond to a wide range of inducers found in in£amed tissues.
The promoter we have adopted consists of the [3247/+20]
fragment from the human sPLA2-IIA gene promoter, which
is induced by the pro-in£ammatory cytokine IL-1L through a
C/EBP site located at [3200/3191] and by the synthetic glu-
cocorticoid Dex through a half-GRE located at [3229/3224],
plus a double PPRE that is stimulated by certain eicosanoids
and prostaglandins. Therefore, the high concentrations of IL-
1L, leukotrienes and prostaglandins produced during in£am-
mation should stimulate the promoter.
We ¢rst constructed the most e⁄cient transcription unit
responding to PPAR activators. The (DR1)2-21 PPRE con-
struct was chosen because of its low basal activity and respon-
siveness to PGJ2 and WY-14643. IL-1L, Dex, PGJ2, WY-
14643 or NSAIDs such as ibuprofen and indomethacin stimu-
lated the (DR1)2-21-sPLA2-IIA chimeric promoter to varying
degrees; some combinations of stimulators had additive ef-
fects. Of particular interest was the transcription elicited in
response to a combination of IL-1L and PGJ2. This resulted
in the greatest promoter activity.
PPARs are involved in the regulation of many crucial phys-
iological and developmental processes [6,17,18]. Although
PPARK and -Q seem to be antagonistic partners in lipid ho-
meostasis [19], both have been implicated in the anti-in£am-
matory process [8,20^22]. The eicosanoid PGJ2 is the most
potent natural ligand of PPARQ described so far and the
chemotactic leukotriene B4 has been implicated in the control
of the in£ammatory response through binding to PPARK.
And, some cyclooxygenase inhibitors belonging to the
NSAIDs family have been identi¢ed as PPAR ligands [10].
Transcription is initiated by cross-talking between inducible
transcription factors and general transcription factors bound
to the promoter. For example, transcription of the rat
CYP2DS P450 is mediated by cooperative interaction between
C/EBPL and SP1 [23]. The sPLA2-IIA gene promoter contains
binding sites for both C/EBP and SP1 [3,4]. The concentra-
tions of C/EBPL and -N increase in most tissues after in£am-
matory stimuli, suggesting that these factors are important in
in£ammation [24]. But, few studies have described the inter-
action between PPAR and C/EBP factors.
Clearly, the human sPLA2-IIA promoter contains several
binding sites for ubiquitous and inducible activation factors
lying a short distance (up to 3200 bp) from the initiation site.
This promoter organization is also reminiscent of that of the
COX-2 promoter studied in our laboratory [25]. This partic-
ular organization provides a good context for cross-talk be-
tween transcription factors, especially through docking to
common co-activator proteins like PGC-1, CBP/p300 and
SRC-1 [26^28]. These interactions between transcription fac-
tors and co-activators, and between co-activators [29], may
cause conformational changes facilitating the recruitment of
the pre-initiation complex and chromatin remodeling.
Therefore, the sPLA2-IIA gene promoter provides an inter-
esting model for driving the expression of a gene that can
reduce in£ammation. The addition of PPAR binding sites
may provide a new tool for coordinating transcription in re-
sponse to selected stimuli. Our ¢ndings show that the PPRE-
sPLA2-IIA chimeric promoter contains enough information to
direct the expression of a curative gene. We also ¢nd that IL-
1L and PGJ2 act synergistically through C/EBP and PPARQ
respectively, in chondrocytes. The results obtained by muta-
tion of the C/EBP binding site con¢rm the central role of
C/EBP factors in stimulating the in£ammatory response
gene promoters of sPLA2-IIA and COX-2 [3,25,30].
Studies with transgenic animals would give us access to the
way the promoter responds to inducers like eicosanoids and
NSAIDs and to screen the e¡ect of new drugs on in£amma-
tory responsive promoters.
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Fig. 4. E¡ects of NSAIDs on the chimeric promoter activity. Pri-
mary cultures of chondrocytes were transiently transfected with
pUC-SH-(DR1)2-21-[3247/+20]-CAT and stimulated with IL-1L (10
ng/ml), indomethacin (1034 M), ibuprofen (1034 M) or a combina-
tion of IL-1L plus a NSAID. Each point is the mean þ S.E.M. of
three independent experiments performed in duplicate. Data are ex-
pressed as fold induction compared to unstimulated cells.
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The promoter described above has been patented by the Universite¤
Pierre et Marie Curie (Patent Number: 00 03262)
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